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Abstract: The binding of the scaffolding protein MO25 to SPAK and OSR1 
protein kinases, which regulate ion homeostasis, causes up to 100-fold 
increase in their catalytic activity. Since various animal models showed that 
the inhibition of SPAK and OSR1 lowers blood pressure, we herein present 
a novel indirect approach for inhibiting SPAK and OSR1 kinases by targeting 
their protein partner MO25.  To explore this approach, we developed 
fluorescent polarization assay and used it in screening a small in-house 
4,000 compounds. This led to the identification of one molecule, 
HK01, as the first small molecule inhibitor of the MO25-dependent 
activation of SPAK and OSR1 in vitro. Our data confirms the feasibility of 
targeting this protein-protein interaction by small molecules and highlights 
the potential of these molecules to modulate ion co- transporters and thus 
cellular electrolyte balance. 
 
STE20/SPS1-related proline-alanine-rich protein kinase (SPAK) and 
oxidative-stress-responsive kinase 1 (OSR1) are two serine/threonine 
protein kinases that share 68% sequence identity.
[1] 
Although under 
normal conditions these kinases are inactive, they become activated by 
osmotic stress via two  distinct mechanisms.
[2] 
First, they get 
phosphorylated in a highly conserved threonine residue in their T-loop 
motifs, SPAK T233 and OSR1 T185, by a family of protein kinases known 
as WNKs.
[3] 
The acquired basal activity obtained following WNK- 
phosphorylation is subsequently further enhanced by 80- to 100- fold 
through the binding to the mouse protein-25 (MO25), a scaffolding 
protein (Fig. 1).
[4] Tǁo isofoƌŵs of MOϮϱ eǆist iŶ huŵaŶs, MOϮϱα     and 
β,  ǁhiĐh aƌe eǆpƌessed iŶ ŵaŶǇ tissues 
mostly in testis, brain, spleen, pancreas and kidney.
[4] 
Both isoforms 
activate SPAK and OSR1 in equal measures.
[4] 
Once fully activated, SPAK 
and OSR1 kinases phosphorylate a series of ion co-transporters such as 
the sodium-potassium-chloride co-transporters 1 and 2 (NKCC1 and 
NKCC2, respectively).
[2]
 
The involvement of SPAK and OSR1 kinases in regulating ion 
homeostasis via the phosphorylation of ion co-transporters and their 
possible roles in the pathogenesis of diseases that involve electrolyte 
imbalance was confirmed when it  was  discovered that genetic 
mutations in the SPAK and OSR1 upstream kinases 
WNKs cause hypertension in humans (Fig.  1).
[5]  
This role   was 
further emphasized by recent reports which revealed that mutations in 
the E3 ubiquitin ligases, Cul-3 and KLHL3, which regulate the protein 
levels of WNK kinases, cause hypertension (Fig.  1).
[6]  
These studies 
suggested that the inhibition of   SPAK 
and OSR1 kinases would lead to reduced blood pressure. This notion 
was confirmed by various SPAK knock-in and knock-out mouse 
models,
[7] 
which collectively indicated that small  molecules that inhibit 
the catalytic activity of SPAK and OSR1 would have the potential to 
lower blood pressure and represent  a new class of antihypertensive 
drugs. 
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Figure 1. A general representation of the WNK-SPAK/OSR1-MO25 signaling cascade 
and its role in the regulation of sodium, potassium and chloride ion co-transporters. 
 
To date, few WNK-SPAK/OSR1 signalling inhibitors have been 
reported. These include those that bind directly to WNK kinases
[8] 
or 
those that bind to SPAK/OSR1 and inhibit downstream WNK-
signalling.
[9] 
In this work, we explored the discovery of small molecules 
that bind to the scaffolding protein MO25 as means of inhibiting its 
binding to SPAK and OSR1 kinases and consequently inhibiting their 
significant MO25- dependent activation. 
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Figure 2. HTS assay optimization and identification of HK01 as an MO25-binder. A. Co-crystal structure of MO25 (beige) in complex with the WEW peptide motif (green sticks) 
derived from human SPAK. B belled 16-mer peptides (TEDGDWEWpSDDEMDEK, 
termed WEWpS or TEDGDAEApSDDEMDEK, termed AEApS). C. Effect of DMSO on the FP signal. D. Stability of the FP signal overtime. FP signal was recorded at 20 and 45 minutes, 
1, 3 and 24 h. E. Chemical structure of HK01. F. In vitro inhibition of MO25 binding to the SPAK 16-mer WEWpS peptide by HK01. G. In vitro ADP-
T185E in the absence or presence of MO25 (five molar excess). Data for   B, C, D, F and G shown are the average signal from triplicates with SD. 
Our pursuit of specific MO25-small molecule binders was inspired by 
the fact that MO25 binding to SPAK and OSR1 kinases is mediated by 
two highly  conserved  tryptophan residues on SPAK (W382 and W384) 
and OSR1 (W336 and W338).
[4] 
Indeed, we recently solved the crystal 
structure of MO25 in complex with the WEW motif of SPAK 
(unpublished data) and this showed that these two tryptophan residues 
sit in a 
hydrophobic site on MO25 (Fig. 2A) akin to how the pseudokinase 
STRADα WEF ŵotif[10] binds to MO25. With this in mind, we developed 
a fluorescence polarization (FP) assay for measuring the binding of 
MO25 to a 16-mer WEWpS peptide derived from SPAK and OSR1, which 
contains the highly conserved  tryptophan  residues.  Briefly,  the  16-
mer     peptide 
(TEDGDWEWpSDDEMDEK) derived from human SPAK (aa. 377-392) 
was synthesised with an N-terminal domain CCPGCCGG  motif  and  was  
This fluorophore-peptide conjugate was 
subsequently incubated with increasing    concentrations    of     MO25     
and fluorescence polarization was measured to determine the binding 
Fig. 2B). We also used a mutated version of 
the peptide where the tryptophan residues were mutated   into alanine  
(TEDGDAEApSDDEMDEK)  and  this  did  not  bind  to MO25  confirming  
the  importance   of   these two  tryptophan residues of SPAK and OSR1 
in mediating binding to MO25 (Fig. 2B). Given that this assay is 
compatible with high throughput screening (HTS) technologies, we next 
employed it in screening 4,000 compounds from our in-house diversity-
set library of small molecules to identify hit small molecule MO25-
binders. 
Prior to running the screen, we first studied the effect of DMSO on 
the FP signal since the library compounds were already dissolved in 
DMSO. For this, the FP assay was run in increasing concentrations of 
DMSO ranging from 0.3% to 10%.  A final concentration of 4 % DMSO 
was chosen as 90% of the  FP signal was retained (Fig. 2C). 
Subsequently, we investigated 
the stability of the FP signal over time. Thus, the assay was read at 
various times ranging from 20 minutes to 24 h and, impressively, the FP 
signal was stable over 24 h (Fig. 2D). 
Next, we screened 4,000 compounds form the University of 
Birmingham in-house diversity-set library of small  molecules. The 
compounds were screened at a single final concentration of 
ϮϬ μM iŶ dupliĐate. Siǆ ĐoŵpouŶds ǁeƌe ideŶtified fƌoŵ the pƌiŵaƌǇ 
screen as possible MO25-binders since they achieved > 30% inhibition 
of MO25 binding to the 16-mer WEWpS peptide. Further analysis of 
these compounds indicated that only one compound, HK01 (Fig. 2E, see 
Supplementary Information), was a true MO25-binder. A prior 
knowledge search using the structure of HK01 and its reported IDs did 
not lead to  any results. Using the in vitro FP competition assay, HK01 
was able to inhibit the 16-mer WEWpS peptide binding to MO25, IC50  = 
78 
± ϰ μM ;Fig. 2F). Interestingly, a series of compounds with structural 
similarity to HK01, especially those with the anthracene moiety, did not 
show any ability to inhibit the 16-mer WEWpS peptide binding to MO25 
at ϭϬϬ μM ;see Supplementary Information). SPR studies showed that 
the KD of HK01 towards wild-tǇpe MOϮϱ ǁas ϭϮϳ ± ϲ μM ;see 
Supplementary Information). 
To explore if this inhibition of binding could be translated into 
inhibition of the catalytic activity of SPAK and OSR1 kinases, we run an 
in vitro kinase assay employing full length OSR1 T185E. We used this 
OSR1 where the T-loop threonine was mutated into glutamic acid, to 
mimic phosphorylation, as it is  constitutively active.
[3] 
In this assay, full 
length OSR1 T185E in the  presence  of   MO25  showed  that   HK01  
exerted     dose- 
dependent inhibition of the MO25-dependent activation of OSR1 T185E 
(Fig. 2G). Although MO25 binding to SPAK and OSR1 kinases is thought 
to be 1:1, previous studies
[4] 
have established that pronounced 
activation of OSR1 T185E in vitro required five molar   access   of   MO25   
and   this   led   us   to   use       high 
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concentrations of the MO25 small molecule binder HK01 (Fig. 2G). 
Interestingly, HK01 was unable to inhibit MST3, a protein kinase that 
belongs to the same family of kinases as SPAK and OSR1, in vitro even 
at ĐoŶĐeŶtƌatioŶs up to ϱϬϬ μM ;see Supplementary Information). 
To further probe the ability of the hit compound HK01 to bind MO25 
and inhibit its binding to SPAK and OSR1 protein kinases, we performed 
MO25 pull down assay in the presence and absence of HK01. For this, 
lysates from HEK293 cells, which endogenously express MO25, were 
incubated with N-terminally biotinylated 16-mer WEWpS peptide in the 
presence of increasing concentrations of HK01. Following 2 h 
incubation, streptavidine-biotin-16-mer WEWpS pulldown was 
performed and the pulled down material underwent blotting for MO25. 
As shown in Fig. 3, in the absence of HK01, endogenous  MO25 was 
pulled down by the 16-mer WEWpS peptide as expected. This binding, 
however, was abolished by the addition of 100 µM unlabeled 16-mer 
WEWpS peptide as expected. Interestingly, titration of increasing 
concentrations of HK01 resulted in the inhibition of MO25 binding to 
the 16-mer WEWpS peptide in a concentration dependent manner. 
Notably, western blotting of the flow through material following the 
streptavidine-biotin pulldown showed higher amounts of MO25 in 
samples where  the MO25 binding to the 16-mer peptide was inhibited 
by the unlabeled 16-mer WEWpS peptide or HK01 (Fig. 3). This confirms 
that HK01 directly binds to MO25 and inhibits its  binding to the 16-mer 
WEWpS peptide in HEK293 cell lysates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Competition of MO25 binding to the SPAK 16-mer WEWpS peptide by HK01. 
HEK293 cell lysates were treated with either the SPAK 16- mer WEWpS peptide or HK01 
at increasing concentrations. This was followed by incubation with the biotinylated 
version of the SPAK 16-mer WEWpS peptide. The pulled down material underwent 
blotting for MO25. The flow through from this pulldown experiment was probed foƌ β-
catenin as a negative control and MO25. 
 
Given the ability of HK01 to indirectly inhibit OSR1 T185E activity in 
vitro through the inhibition of its binding to MO25, we next investigated 
the ability of HK01 to inhibit the  phosphorylation of SPAK and OSR1 
physiological substrates in cells. In particular, we focused on the 
inhibition of the sodium, potassium and chloride co-transporter NKCC1, 
a known in vivo substrate of SPAK and OSR1 kinases.
[3]  
For this 
experiment, we 
used HEK293 cells as they endogenously express  WNK kinases, SPAK, 
OSR1, MO25 and NKCC1.
[4] 
The cells were treated with increasing 
ĐoŶĐeŶtƌatioŶs of HKϬϭ oƌ ϭϬ μM of STOCKϭS-50699[9a] for 30 minutes 
followed by hypotonic buffer to activate WNK-SPAK/OSR1 signaling.
[11] 
Subsequently, they were harvested and probed for total SPAK, SPAK 
pS373,    total 
NKCC1 and NKCC1 pT203, pT207 and pT212. The  results show that 
hypotonic buffer led to a pronounced increase in the phosphorylation 
of SPAK pS373 and NKCC1 at the T203, T207 and T212 residues 
indicating the activation of the WNK- SPAK/OSR1 signaling cascade (Fig. 
4). 
These phosphorylation sites were suppressed in samples treated with 
the WNK-signaling inhibitor
[9b] 
STOCK1S-50699 as expected. The 16-
mer WEWpS peptide, however, showed no inhibition of NKCC1 or SPAK 
S373 phosphorylation most likely due to lack of cellular uptake because 
of its molecular weight of approximately 1800 g/mol. Interestingly, the 
phosphorylation of NKCC1 at T203, T207 and T212 sites was inhibited 
by HK01   in 
concentration-dependent manner with the SPAK/OSR1- mediated 
phosphorylation of NKCC1 being completely inhibited at high 
concentrations. Critically, unlike STOCK1S-50699, HK01 had no 
significant effects on SPAK S373 phosphorylation confirming that it 
does not inhibit WNK kinases or their binding to SPAK. This reflects the 
ability of HK01 to inhibit MO25- dependent activation of SPAK and OSR1 
kinases. Notably, the HK01 was not toxic as the cells were healthy even 
at the high concentrations (2 mM) of HK01 and its effects seem to be 
specific to MO25 binding since there was no effect on the total levels 
of beta-catenin, a protein unrelated to the WNK- SPAK/OSR1-signalling 
pathway (Fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Inhibition of SPAK/OSR1 kinases in HEK293 cells by HK01. HEK293 cells were 
treated with the WNK-signaling inhibitor STOCK1S50699 (10 µM), SPAK 16-mer 
WEWpS peptide ;ϭϬϬ μMͿ oƌ HKϬϭ at diffeƌeŶt ĐoŶĐeŶtƌatioŶs ;Ϭ.ϭ-2 mM) for 30 
minutes. Subsequently, they were either left untreated or treated with hypotonic 
buffer for 30 minutes to activate WNK- SPAK/OSR1 signaling. The cells were then 
harvested and the lysates were probed for phospho-NKCC1 T203, T207 and T212, total 
NKCCϭ, β-catenin, phospho-SPAK S373, total SPAK and MO25. 
 
In conclusion, the work presented herein confirms the possibility of 
targeting the scaffolding protein MO25 with small molecules, which 
consequently leads to the inhibition of SPAK and OSR1. Indeed, we have 
shown that compound HK01 can successfully inhibit MO25 binding to 
SPAK and OSR1 leading to their in vitro inhibition without directly 
binding to them. Efforts aimed at the structural optimization of HK01 
to achieve better binding affinity are currently ongoing and will be 
reported in the future. Collectively, our work represents a novel 
strategy in    the 
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discovery of indirect SPAK and OSR1 inhibitors, which have the 
potential to be developed into new antihypertensive drugs. 
 
 
Experimental Section 
Reagents 
Tissue-culture reagents and protein expression materials were  purchased from 
Sigma Aldrich. Peptides were ordered from GLS Peptide Synthesis (China). 
STOCK1S-50699 was purchased from Vitas-M Laboratory, Ltd. ADP-Glo™ KiŶase 
Assay kit was purchased from Promega. LumioTM Green (FlAsH-EDT2) was 
purchased from Carbosynth. HK01 was purchased from ChemBridge 
(ID:7182449). 
Buffers 
Cells Lysis Buffer: 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 1 mM   EGTA, 
50 mM sodium fluoride, 5 mM sodium pyrophosphate, 1 mM sodium 
orthovanadate, 1% (w/v) Nonidet P40, 0.27 M sucrose, 0.1% (v/v) 2- 
mercaptoethanol, 0.1 mM PMSF, 1 mM benzamidine. Bacterial lysis buffer: 50 
mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EGTA,  1 mM EDTA, 0.27 M sucrose, 
0.1 mM PMSF, 1 mM benzamidine, 0.5 mg/ml lysosome, 0.3 mg/ml DNase and 
2mM DTT. Buffer A:  50 mM Tris-HCl (pH 7.5), 0.1 mM EGTA and 0.1% (v/v) 2-
mercaptoethanol.  Normal buffer: bacterial lysis buffer without lysozome and 
DNase. High  salt buffer: normal buffer with 500 mM NaCl. TBS-T buffer: 50 mM 
Tris-HCl (pH 7.5), 150 mM NaCl and 0.2% (v/v) Tween-20. Running buffer: 34.6 
mM SDS, 25 mM Tris-base and 1.92 M glycine. Transfer buffer: 48 mM Tris-base, 
39 mM glycine containing 20% (v/v) methanol. Hypotonic low- chloride buffer: 
67.5 mM sodium gluconate, 2.5 mM potassium gluconate, 
0.25 mM CaCl2, 0.25 mM MgCl2, 0.5 mM Na2HPO4, 0.5 mM Na2SO4  and 
7.5 mM HEPES. SDS sample buffer (4X): 40 % glycerol, 240 mM Tris- HCl (pH 6.8), 
8% SDS, 0.04% (w/v) bromophenol blue and 5% 2- mercaptoethanol. Blocking 
buffer: 10% (w/v) dried skimmed milk in TBST. Dialysis buffer: 50 mM Tris-HCl 
(pH 7.5), 150 mM NaCl and 2 mM DTT. Antibodies 
SPAK phospho-Seƌϯϳϯ [SϲϳϬB], MOϮϱα [SϴϵϴA], NKCCϭ [DU 6146], NKCC1 
phospho-Thr 203+Thr 207+Thr 212 [S763B] and SPAK  [S551D] 
antibodies were purchased from DSTT, University of Dundee. SPAK [2281S] and 
β-Catenin [9562S] were purchased from Cell Signalling Technology, GAPDH 
antibody [MA5-15738], anti-sheep [31480] and anti- rabbit [31460] secondary 
antibodies conjugated to HRP were purchased from Thermo Scientific. 
Plasmids, protein expression and purification 
pGEX-6-MO25alpha [DU2945] DNA plasmid was purchased from the DSTT, 
University of Dundee and the protein was expressed and purified in-house as 
described elsewhere
[10]
. The OSR1 T185E protein [DU6231] was purchased from 
the DSTT, University of Dundee. 
Development of fluorescence polarization assay: 
BMG PheraStar plate reader was used to measure the fluorescence polarization, 
with an excitation and emission wavelengths of 485 nm and 538 nm, 
respectively. Assays were performed using black, flat bottom Greiner 384-well 
plates in triplicate with at least twelve data points per curve and data analysis 
was completed using GraphPad Prism 7.0. 
Peptide labelling and determination of optimum fluorescent probe 
concentration 
The 16-mer TEDGDWEWpSDDEMDEK peptide derived from human SPAK (aa. 
377-392) was synthesised with an N-terminal CCPGCCGG domain. The lyophilized 
peptide was initially suspended in 50 mM NH4HCO3  (pH 8). The labelling step was 
aĐhieǀed ďǇ iŶĐuďatiŶg ϭϬ μM  of peptide ǁith ϯϬ μM of FlAsH-EDT2 iŶ ϱϬϬ μL 
dialysis buffer in the dark at 4°C for 2 h. The peptides were then dialyzed for 4 h 
into dialysis buffer using a Mini Dialysis kit with 1 kD cut-off (GE Healthcare) and 
then for another 12 h with a fresh dialysis buffer. The optimum FlAsH-EDT2 
labelled peptide concentration for FP assay was determined to be 10nM as this 
concentration exhibited about ten times more fluorescence intensity signal 
compared to background controls. 
Fluorescence polarization binding and stability studies 
10 nM of FlAsH-EDT2-labelled peptide (TEDGDWEWpSDDEMDEK or 
TEDGDAEApSDDEMDEK)    was     mixed    with    MO25    at     various 
concentrations (0.005-ϱϬ μMͿ iŶ dialǇsis ďuffeƌ iŶ a fiŶal ǀoluŵe of ϯϬ μL. The 
plates were incubated at RT and readings were taken at various time points.
[12]
 
DMSO tolerance 
Increasing concentrations of DMSO (0%–10% of assay volume) were added to the 
reaction mixture containing 10 nM of the FlAsH-EDT2 labelled 16-mer peptide 
;TEDGDWEWpSDDEMDEKͿ aŶd ϱμM MOϮϱ pƌoteiŶ. The ƌeaĐtioŶ ŵiǆtuƌe ǁas 
incubated at RT for 2 h and then fluorescence polarization measurements were 
taken. 
Fluorescence polarization competition studies 
Coŵpetitiǀe ďiŶdiŶg eǆpeƌiŵeŶts ǁeƌe peƌfoƌŵed iŶ a total of Ϯϱ μL dialǇsis 
buffer. Fluorescent peptide and MO25 were used at final concentrations of 10nM 
and 5 µM respectively and DMSO was added to all wells and kept at final 
concentration of 4%. 0.05% of Tween-20 was used in the FP assay to prevent 
aggregation. For each assay, blank controls contained the fluorescent peptide 
only; negative controls contained the fluorescent peptide and MO25 while the 
16-mer WEWpS was added to the fluorescent peptide and MO25 for positive 
controls. The effect of the competitors on the disruption of the interaction is 
expressed as % of control. This latter (% of control) for each dose of competitor 
was calculated using the following equation: 
% of control = (recorded FPsignal competitor - recorded FPsignal blank)/(recorded FPsignal 
control -recorded FPsignal blank) 
Where recorded FP signal blank is the average measured FP signal from 
fluorescent peptide only wells, the recorded FP signal control is the average FP 
signal from wells containing MO25 and fluorescent peptide in the absence of 
inhibitors, the recorded FP signal competitor is the FP signal from wells 
containing MO25 and fluorescent peptide in the presence of competitors. Dose-
dependent experiments to determine the IC50 for HK01 were performed in the 
same manner using at least 12 concentrations in 2-fold serial dilutions from 1000 
μM. After 2 h incubation at room temperature, the fluorescence polarization 
measurements were taken as described above. 
Assay performance 
Z' factor was used to evaluate the assay quality and was calculated to be 
0.7 indicating the robustness of the assay.
[13] 
This reported Z' factor is the average 
of 3 experiments of 16 replicates performed on different days. It was determined 
based on the following equation: 
Z'= 1 – ;ϯσpositive + ϯσnegative) / |µpositive- µnegative| 
Wheƌe σ aŶd µ aƌe the staŶdaƌd deǀiatioŶs aŶd ŵeaŶs of the Ŷegative (FlAsH-
EDT2-labelled peptide bound to MO25 in 4% DMSO) and positive (FlAsH-EDT2-
labelled peptide bound to MO25 in the presence of SPAK 16-mer WEWpS 
peptide) controls respectively. 
Pull-down assay 
Streptavidin beads were washed with Buffer A three times. 1.2 mg of HEK293 
cells were pre-cleared using the prewashed streptavidin beads then divided into 
equal amounts using Eppendorf tubes. The tubes were then incubated with 100 
µM 16-mer WEWpS peptide as a positive control or increasing concentrations of 
HK01 (0.05 mM, 0.1 mM, 0.25 mM, 0.75 mM, 1 mM and 2 mM) for 2 h. 3 µg of 
the biotinylated 16-mer WEWpS was added to each sample for 10 mins at 4 ºC. 
20 µL of the washed streptavidin beads slurry was added to each sample and 
mixed with roller-shaker at 4 ºC. Following a spin-down at 3000 rpm, for 10 mins,  
the supernatant was collected and concentrations were determined using 
Bradford assay. The beads were washed 3 times more with buffer A. Using 4x 
SDS, samples were prepared for immunoblotting. 
Cell based assays 
HEK-293 cells were cultured using 6-well plates in DMEM supplemented with 
10% (v/v) FBS, 2 mM L-glutamine, 100 units/mL penicillin and 0.1 mg/mL 
streptomycin at 37 °C in a humidified 5% CO2 incubator. Cells were incubated 
with STOCK1S50699 (10 µM), SPAK 16-ŵeƌ WEWpS peptide ;ϭϬϬ μMͿ oƌ HKϬϭ at 
increasing concentrations (0.1 mM, 0.25 mM, 0.5 mM, 0.75 mM, 1 mM and 2 
mM) for 30 minutes then stimulated with low chloride hypotonic buffer to 
activate WNK signalling for 30 minutes. Cells were then lysed with 200 µL cells 
lysis buffer and centrifuged at 12000 g at 4 ºC for 10 minutes and the supernatant 
was collected. 
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Immunoblotting 
ϮϬ μg of Đell lǇsates iŶ SDS saŵple ďuffeƌ ǁeƌe suďjeĐted to eleĐtƌophoƌesis oŶ a 
polyacrylamide gel and transferred to nitrocellulose membranes. The 
membranes were blocked for 1 h with 10% (w/v) skimmed milk powder in TBS-
T. The membranes were then incubated with the relevant primary antibodies 
overnight. The blots were then washed six times with TBS-T to remove the 
pƌiŵaƌǇ aŶtiďodǇ aŶd suďseƋueŶtlǇ iŶĐuďated ǁith seĐoŶdaƌǇ  HRP‐ĐoŶjugated  
antibodies. After repeating the washing steps, the signal was detected with the 
enhanced chemiluminescence reagent. Immunoblots were developed using a 
filŵ autoŵatiĐ pƌoĐessoƌ ;SRX‐ϭϬϭ; KoŶiĐa MiŶolta MediĐalͿ, aŶd filŵs ǁeƌe 
sĐaŶŶed ǁith a ϯϬϬ‐dpϭ ƌesolutioŶ oŶ a sĐaŶŶeƌ ;PoǁeƌLook ϭϬϬϬ; UMAXͿ. 
ADP-Glo in vitro kinase assay 
The  kinase  activity  was  assayed  using  ADP-  96- 
well plate in triplicate as reported.
[4] 
HK01 was tested at 100 µM and 500 µM final 
concentrations against GST-OSR1 T185E (0.4 µM final concentration) in the 
presence and absence of 5x MO25 (2 µM final concentration). Kinase reactions 
ǁeƌe peƌfoƌŵed foƌ ϰϬ ŵiŶutes at ϯϬ °C ǁith geŶtle agitatioŶ iŶ Ϯϱ μL ƌeaĐtioŶ 
buffer consisting of 50 mM Tris-HCl, 10m MgCl2, 0.1% (v/v) 2-mercaptoethanol, 
0.1 mM ATP and   employing 
0.25  mM  CATCHtide  (RRHYYYDTHTNTYYLRTFGHNTRR).  The plate 
was then developed according to the manufacturer's protocol
[14]
. The plate was 
subsequently read on a BMG FLUOstar Omega plate reader. The final DMSO 
concentration was 4%. 
 
 
Acknowledgements 
We would like to thank the MRC for funding parts of this project 
through an MRC Confidence of Concept Grant (reference 
MC_PC_14107). We are also grateful to the Birmingham Protein 
Expression Facility (PEF) for help with protein production. NSS would 
like to thank the Royal Society for the award of an  Industry Fellowship. 
 
Keywords: MOϮϱ • SĐaffoldiŶg • IŶhiďitoƌ • SPAK • OSRϭ 
 
[1] J. Boudeau, A. F. Baas, M. Deak, N. A. Morrice, A. Kieloch, M. 
Schutkowski, A. R. Prescott, H. C. Clevers, D. R. Alessi, EMBO J. 2003, 22, 
5102-5114. 
[2] D. R. Alessi, J. Zhang, A. Khanna, T. Hochdorfer, Y. Shang, K. T. Kahle, Sci 
Signal 2014, 7, re3. 
[3] A. C. Vitari, M. Deak, N. A. Morrice, D. R. Alessi, Biochem. J 
2005, 391, 17-24. 
[4] B. M. Filippi, P. de los Heros, Y. Mehellou, I. Navratilova, R. Gourlay, M. 
Deak, L. Plater, R. Toth, E. Zeqiraj, D. R. Alessi, EMBO J. 2011, 30, 1730-
1741. 
[5] F. H. Wilson, S. Disse-Nicodeme, K. A. Choate, K. Ishikawa, C. Nelson-
Williams, I. Desitter, M. Gunel, D. V. Milford, G. W. Lipkin, 
J. M. Achard, M. P. Feely, B. Dussol, Y. Berland, R. J. Unwin, H. Mayan, 
D. B. Simon, Z. Farfel, X. Jeunemaitre, R. P. Lifton, Science 2001, 293, 
1107-1112. 
[6] aL. M. Boyden, M. Choi, K. A. Choate, C. J. Nelson-Williams, A. Farhi, H. 
R. Toka, I. R. Tikhonova, R. Bjornson, S. M. Mane, G. Colussi, M. Lebel, 
R. D. Gordon, B. A. Semmekrot, A. Poujol, M. 
J. Valimaki, M. E. De Ferrari, S. A. Sanjad, M. Gutkin, F. E. Karet, J. R. 
Tucci, J. R. Stockigt, K. M. Keppler-Noreuil, C. C. Porter, S. K. Anand, M. 
L. Whiteford, I. D. Davis, S. B. Dewar, A. Bettinelli, J. J. Fadrowski, C. 
W. Belsha, T. E. Hunley, R. D. 
Nelson, H. Trachtman, T. R. Cole, M. Pinsk, D. Bockenhauer, M. Shenoy, 
P. Vaidyanathan, J. W. Foreman, M. Rasoulpour, F. Thameem, H. Z. Al-
Shahrouri, J. Radhakrishnan, A. G. Gharavi, 
B. Goilav, R. P. Lifton, Nature 2012, 482, 98-102; bH. Louis-Dit- Picard, 
J. Barc, D. Trujillano, S. Miserey-Lenkei, N. Bouatia-Naji, 
O. Pylypenko, G. Beaurain, A. Bonnefond, O. Sand, C.   Simian, 
E. Vidal-Petiot, C. Soukaseum, C. Mandet, F. Broux, O. Chabre, 
M. Delahousse, V. Esnault, B. Fiquet, P. Houillier, C. I. Bagnis, J. Koenig, 
M. Konrad, P. Landais, C. Mourani, P. Niaudet, V.  Probst, C. Thauvin, R. 
J. Unwin, S. D. Soroka, G. Ehret, S. Ossowski, M. Caulfield, P. 
International Consortium for Blood, P. Bruneval, X. Estivill, P. Froguel, J. 
Hadchouel, J. J. Schott, X. Jeunemaitre, Nat Genet 2012, 44, 456-460, 
S451-453; cA. Ohta, 
F. R. Schumacher, Y. Mehellou, C. Johnson, A. Knebel, T. J. Macartney, 
N. T. Wood, D. R. Alessi, T. Kurz, Biochem. J 2013; dS. Shibata, J. Zhang, 
J. Puthumana, K. L. Stone, R. P. Lifton, Proc Natl Acad Sci U S A 2013; 
eM. Wakabayashi, T. Mori, K. Isobe, E. Sohara, K. Susa, Y. Araki, M. 
Chiga, E. Kikuchi, N. Nomura, Y. Mori, H. Matsuo, T. Murata, S. Nomura, 
T. Asano, H. Kawaguchi, S. Nonoyama, T. Rai, S. Sasaki, S. Uchida, Cell  
Rep 2013. 
[7] aF. H. Rafiqi, A. M. Zuber, M. Glover, C. Richardson, S. Fleming, 
S. Jovanovic, A. Jovanovic, K. M. O'Shaughnessy, D. R.  Alessi, 
EMBO Mol Med 2010, 2, 63-75; bS. S. Yang, Y. F. Lo, C. C. Wu, 
S. W. Lin, C. J. Yeh, P. Chu, H. K. Sytwu, S. Uchida, S. Sasaki, S. H. Lin, J 
Am Soc Nephrol 2010, 21, 1868-1877. 
[8] aK. Yamada, H. M. Park, D. F. Rigel, K. DiPetrillo, E. J. Whalen, 
A. Anisowicz, M. Beil, J. Berstler, C. E. Brocklehurst, D. A. Burdick, S. L. 
Caplan, M. P. Capparelli, G. Chen, W. Chen, B. Dale, L. Deng, F. Fu, N. 
Hamamatsu, K. Harasaki, T. Herr, P. Hoffmann, Q. Y. Hu, W. J. Huang, N. 
Idamakanti, H. Imase, Y. Iwaki, M. Jain, J. Jeyaseelan, M. Kato, V. K. 
Kaushik, D.   Kohls, 
V. Kunjathoor, D. LaSala, J. Lee, J. Liu, Y. Luo, F. Ma, R. Mo, S. Mowbray, 
M. Mogi, F. Ossola, P. Pandey, S. J. Patel, S. Raghavan, B. Salem, Y. H. 
Shanado, G. M. Trakshel, G. Turner, 
H. Wakai, C. Wang, S. Weldon, J. B. Wielicki, X. Xie, L. Xu, Y. I. Yagi, K.
Yasoshima, J. Yin, D. Yowe, J. H. Zhang, G. Zheng, L. Monovich, Nat Chem
Biol 2016; bK. Yamada, J. H. Zhang, X. Xie, J. Reinhardt, A. Q. Xie, D. 
LaSala, D. Kohls, D. Yowe, D. Burdick, H. Yoshisue, H. Wakai, I. Schmidt, 
J. Gunawan, K. Yasoshima, Q. K. Yue, M. Kato, M. Mogi, N. Idamakanti, 
N. Kreder, P. Drueckes, P. Pandey, T. Kawanami, W. Huang, Y. I. Yagi, Z. 
Deng, H. M. Park, ACS Chem Biol 2016. 
[9] aT. Mori, E. Kikuchi, Y. Watanabe, S. Fujii, M.   Ishigami-Yuasa, 
H. Kagechika, E. Sohara, T. Rai, S. Sasaki, S. Uchida, Biochem. J 2013, 
455, 339-345; bE. Kikuchi, T. Mori, M. Zeniya, K.  Isobe, 
M. Ishigami-Yuasa, S. Fujii, H. Kagechika, T. Ishihara, T. Mizushima, S. 
Sasaki, E. Sohara, T. Rai, S. Uchida, J Am Soc Nephrol 2015, 26, 1525-
1536. 
[10] C. C. Milburn, J. Boudeau, M. Deak, D. R. Alessi, D. M. van Aalten, Nat 
Struct Mol Biol 2004, 11, 193-200. 
[11] A. Zagorska, E. Pozo-Guisado, J. Boudeau, A. C. Vitari, F. H. Rafiqi, J. 
Thastrup, M. Deak, D. G. Campbell, N. A. Morrice, A. R Prescott, D. R. 
Alessi, J. Cell Biol. 2007, 176, 89-100. 
[12] J. Zhang, K. Siew, T. Macartney, K. M. O'Shaughnessy, D. R. Alessi, Hum 
Mol Genet 2015, 24, 4545-4558. 
[13] J.  H.  Zhang, T.  D.  Chung, K.  R. Oldenburg,  J Biomol Screen 
1999, 4, 67-73. 
[14] H. Zegzouti, M. Zdanovskaia, K. Hsiao, S. A. Goueli, Assay Drug Dev 
Technol 2009, 7, 560-572. 
 
 
 
 
 
 
 
For internal use, please do not delete. Submitted_Manuscript 
COMMUNICATION 
 
 
COMMUNICATION 
 
HTS screening of a small library of 4,000 
compounds led to the identification of 
one molecule, HK01, as a promising 
binder to the scaffolding protein MO25. 
This molecule was able to inhibit 
MO25- dependent activation of SPAK 
and OSR1 protein kinases in vitro and in 
cells. Collectively, this confirms that 
MO25 is amenable to targeting by small 
molecules and this approach could 
yield useful SPAK and OSR1 indirect 
kinase inhibitors. 
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